Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer
jRCT2091220115Phase 1Completed
- Sponsor
- Wakayama Medical University
- Start
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of OTSGC-A24 in gastric adenocarcinoma and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Wakayama Medical University. Primary endpoint: Adverse Event and Adverse Drug Reaction. Started Mar 2013; status: completed.
02
Drugs
OTSGC-A24
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2091220115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220115.